Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$31.27 ▼ -1.34
(-4.11%)
MKT CAP: $1.61B • VOL: 1.29M
52W L $28 52W H $41
IMCR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $400.0M | $310.2M | $249.4M |
| YoY Revenue Growth % | +29.0% | +24.4% | — |
| Gross Profit | $394.9M | $307.5M | — |
| Gross Margin % | 98.0% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$45.4M | -$70.5M | -$59.6M |
| Operating Margin % | -11.3% | -22.7% | -23.9% |
| Net Income (GAAP) | -$35.5M | -$51.1M | -$55.3M |
| EBITDA (Normalized) | -$41.9M | -$66.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.7M | $26.1M | $2.9M |
| Capital Expenditures (CapEx) | $4.3M | $5.2M | — |
| Free Cash Flow (FCF) | -$15.1M | $20.9M | $2.9M |
| FCF Margin % | -3.8% | 6.7% | 1.2% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $467.7M | $455.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $381.0M | $360.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IMCR.